Recce Pharmaceuticals

Recce Pharmaceuticals LT Debt/Equity

The Long-Term Debt to Equity Ratio of Recce Pharmaceuticals (RCE.AX) as of Nov 22, 2026 is -0.50. In the previous year, Long-Term Debt to Equity Ratio was -2.95 — a change of -83.20% (higher).

LT Debt/Equity

-0.50

YoY

-83.20%

Last updated:

Long-Term Debt to Equity Ratio of Recce Pharmaceuticals is 2026 -0.50 . Long-Term Debt to Equity Ratio of Recce Pharmaceuticals was 2025 -2.95 . It decreases by -83.20% higher compared to the previous year.

The Recce Pharmaceuticals LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2019
0.00 AUD
Jan 1, 2020
0.00 AUD
Jan 1, 2021
0.00 AUD
Jan 1, 2022
0.00 AUD
Jan 1, 2023
-0.04 AUD
Jan 1, 2024
-0.06 AUD
Jan 1, 2025
-2.95 AUD
Jan 1, 2026
-0.50 AUD
The Recce Pharmaceuticals LT Debt/Equity history
YEARLT Debt/EquityYoY
-0.50-83.20%
-2.95+4,692.95%
-0.06+55.41%
-0.04—
0.00-100.00%
0.00—
0.00—
0.00—
0.00-100.00%
0.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recce Pharmaceuticals stock

Long-Term Debt to Equity Ratio of Recce Pharmaceuticals is -0.50 in 2026.

Long-Term Debt to Equity Ratio of Recce Pharmaceuticals changed from -2.95 to -0.50, representing a -83.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Recce Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Recce Pharmaceuticals

All Key Metrics — Recce Pharmaceuticals